April 24, 2014 1:44 PM ET

Pharmaceuticals

Company Overview of Jennerex Biotherapeutics, Inc.

Company Overview

Jennerex Biotherapeutics, Inc. focuses on the development and commercialization of oncolytic products for cancer. Its pipeline includes JX-594 for treating patients with liver and colorectal cancer; JX-929 for treating patients with pancreatic cancer; JX-1395 for treating patients with prostate cancer; and JX-next generation therapeutic classes for treating patients with various other cancers. The company’s products are designed to attack cancer tumors through synergistic and complementary mechanisms of action, such as lysis of cancer cells through viral replication, reduction of the blood supply to tumors through vascular targeting and destruction, and stimulation of the body's immune respo...

450 Sansome Street

16th Floor

San Francisco, CA 94111

United States

Phone:

415-281-8886

Key Executives for Jennerex Biotherapeutics, Inc.

Chief Executive Officer
Age: 49
Chief Financial Officer and Senior Vice President
Age: 48
Chief Operating Officer
Executive Vice President of Corporate Strategy
Age: 64
Compensation as of Fiscal Year 2013.

Jennerex Biotherapeutics, Inc. Key Developments

Jennerex Biotherapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013

Jennerex Biotherapeutics, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States. Speakers: Laurent Fischer, Chief Executive Officer, President and Director.

Jennerex Biotherapeutics, Inc. Announces Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet its Primary Endpoint

Jennerex Biotherapeutics, Inc. announced that TRAVERSE, a randomized Phase 2b study of Pexa-Vec in second-line, advanced liver cancer patients had reached the pre-specified number of events for analysis. The study failed to meet its primary endpoint of overall survival for Pexa-Vec plus best supportive care (BSC) compared to BSC. Pexa-Vec was generally well tolerated with an adverse event profile consistent with previous Pexa-Vec studies in patients with advanced liver cancer. Additional analyses will be conducted to further understand these data. Pexa-Vec is also being investigated in Phase 2 studies in colorectal, kidney and ovarian cancer. Jennerex will continue to advance the Pexa-Vec program in these indications while evaluating the Pexa-Vec liver cancer program. The Jennerex pipeline also includes JX-929, an oncolytic immunotherapy in Phase 1 clinical trials, and a platform for novel oncolytic and antibody-based immunotherapies.

Jennerex Biotherapeutics, Inc. Presents at Canaccord Genuity 33rd Annual Growth Conference, Aug-15-2013 01:30 PM

Jennerex Biotherapeutics, Inc. Presents at Canaccord Genuity 33rd Annual Growth Conference, Aug-15-2013 01:30 PM. Venue: InterContinental Boston, 520 Atlantic Avenue, Boston, MA 02110, United States.

Similar Private Companies By Industry

Company Name Region
BPR Health International, Inc. United States
Troy Manufacturing Inc. United States
Chiral Quest Corp. United States
Warner Chilcott Holdings Company III, Limited United States
Braeburn Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 25, 2013
--
Private Placement
May 23, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Jennerex Biotherapeutics, Inc., please visit www.jennerex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.